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Abstract
Introduction Cardiovascular disease (CVD) is a major cause of
premature mortality among Systemic lupus erythematosus
(SLE) patients. Many studies have measured and evaluated risk
factors for premature subclinical atherosclerosis, but few
studies are prospective and few have evaluated risk factors for
hard endpoints, i.e. clinically important cardiovascular events
(CVE). We investigated the impact of traditional and lupus
associated risk factors for the first ever CVE in a longitudinal
cohort of SLE patients.
Methods A total of 182 SLE patients (mean age 43.9 years)
selected to be free of CVE were included. Cardiovascular and
autoimmune biomarkers were measured on samples collected
after overnight fasting at baseline. Clinical information was
collected at baseline and at follow up. End point was the first
ever CVE (ischemic heart, cerebrovascular or peripheral
vascular disease or death due to CVD). Impact of baseline
characteristics/biomarkers on the risk of having a first CVE was
evaluated with Cox regression.
Results Follow up was 99.5% after a mean time of 8.3 years.
Twenty-four patients (13%) had a first CVE. In age-adjusted Cox
regression, any positive antiphospholipid antibody (aPL),
elevated markers of endothelial activation (von Willebrand factor
(vWf), soluble vascular cellular adhesion molecule-1 (sVCAM-
1)) and fibrinogen predicted CVEs. Of SLE manifestations,
arthritis, pleuritis and previous venous occlusion were positively
associated with future CVEs while thrombocytopenia was
negatively associated. Among traditional risk factors only age
and smoking were significant predictors. In a multivariable Cox
regression model age, any positive aPL, vWf and absence of
thrombocytopenia were all predictors of the first CVE.
Conclusions In addition to age, positive aPL, biomarkers
indicating increased endothelial cell activity/damage, and
absence of thrombocytopenia were independent predictors of
CVEs in this prospective study. Our results indicate that
activation of the endothelium and the coagulation system are
important features in SLE related CVD. Furthermore, we
observed that the risk of CVEs seems to differ between
subgroups of SLE patients.
aCL: anticardiolipin antibodies; ANA: antinuclear antibodies; ApoB/ApoA: apolipoproteinB/A; APS: anti-phospholipid syndrome; aPL: antiphosphol-
ipid antibody; β2GP1: β2-glycoprotein1; C: complement factor; C3d: complement factor 3 degradation products; CAD: coronary artery disease; CI: 
confidence interval; CVD: cardiovascular disease; CVE: cardiovascular event; dsDNA: anti-double-stranded DNA; ELISA: enzyme-linked immuno-
sorbent assays; GPL/MPL: standardized unit used for measuring anticardiolipin antibodies (one unit approximated to 1 g of immunoglobulin G (IgG) 
(for GPL) or IgM (for MPL) anticardiolipin antibody purified from 1 mL of serum.); HDL: high density lipoprotein; HR: hazard ratio; HRP: horseradish 
peroxidase; hsCRP: high sensitivity C reactive protein; ICVD: ischemic cerebrovascular disease; IFL: immunofluorescence; IHD: ischemic heart dis-
ease; IL-6: interleukin 6; IPVD: ischemic peripheral vascular disease; LAC: lupus anticoagulant; LDL: low density lipoprotein; MDRD: estimated 
glomerular filtration rate using the Modification of Diet in Renal Disease formula; RNP: ribonucleoprotein; SAA: serum amyloid A; SLAM: systemic 
lupus activity measure; SLE: systemic lupus erythematosus; SLICC: systemic lupus international collaborating clinics damage index; Sm: Smith; SSA/
SSB: Sjögren's syndrome A and B; sVCAM-1: soluble vascular cell adhesion molecule 1; vWf: von Willebrand factor.Arthritis Research & Therapy    Vol 11 No 6    Gustafsson et al.
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Introduction
Systemic lupus erythematosus (SLE) is a heterogeneous
chronic systemic autoimmune disease, which mainly affects
women (90%). As treatment for lupus itself has gradually
improved, mortality rates have declined and cardiovascular co-
morbidity has become a growing clinical problem. Circulatory
diseases are today a leading cause of mortality among SLE
patients [1,2].
Traditional coronary artery disease (CAD) risk factors are more
prevalent among SLE patients than in the general population
[3,4] but they do not alone account for the high incidence of
premature cardiovascular disease (CVD) seen in SLE [5,6].
Additionally, several SLE associated risk factors have been
identified such as pro-thrombotic antiphospholipid antibodies
(aPL) [4,7,8], accelerated endothelial cell apoptosis and
impaired repair of damaged endothelium [9,10], oxidized low
density lipoprotein (LDL) [11], pro-inflammatory high density
lipoprotein (HDL) [12], genetic susceptibility [13] and
decreased endothelial binding of annexin V [14]. The role of
these and other mechanisms for premature cardiovascular
morbidity and mortality seen in SLE are presently under
intense study by many research groups.
Prospective studies that evaluate both traditional and lupus
associated risk factors for hard endpoints, that is, CVEs, are to
date relatively few in SLE [8,15,16] and outnumbered by stud-
ies focused on subclinical atherosclerosis in these patients
[4,17,18]. But, measurements of atherosclerosis are surro-
gate markers of CVD and given the complexity of SLE, accel-
erated atherosclerosis may not be the only biologically
plausible connection to CVEs. Other factors in an immunolog-
ically active setting like SLE may influence the likelihood of
CVEs. It is therefore important to perform longitudinal studies
in well-characterized SLE patients and to use hard endpoints
such as myocardial infarction and stroke.
In a single center cohort of SLE patients, we selected patients
free from clinical CVD and investigated the impact of tradi-
tional CAD risk factors, lupus associated biomarkers and clin-
ical manifestations/features on the risk of presenting with a
first ever CVE during eight years of follow-up.
Materials and methods
Patients
All SLE patients at the Department of Rheumatology, Karolin-
ska University Hospital who fulfilled four or more of the 1982
revised American College of Rheumatology Criteria for classi-
fication of SLE [19] during the inclusion period (1995-99)
were asked to participate. A total of 182 of 208 (87.5%) par-
ticipants were free of previous CVEs and were included in this
study. 94% of the patients were European Caucasians and six
percent were of Asian origin.
At follow-up (2004-2007) living patients were reinvestigated
in person when possible. If not, they were interviewed by tele-
phone. Medical charts were reviewed for all patients and death
certificates were collected from all deceased patients.
Autopsy protocols were collected when available. The Local
Ethics Committee of the Karolinska University Hospital
approved the study. All patients gave informed consent to par-
ticipate.
Data collection
At baseline, patients were interviewed and examined by a
rheumatologist who evaluated disease activity using Systemic
Lupus Activity Measure (SLAM) [20] and organ damage with
Systemic Lupus International Collaborating Clinics damage
index (SLICC) [21]. A SLAM score >6 was considered as
active disease [22]. Blood samples were taken after overnight
fasting and laboratory examinations were performed blinded,
either on fresh blood samples or after storage in -70°C. When
stored samples were used (see Table 1), all samples were fro-
zen and each investigation was carried out in one session.
Outcome measures of CVE
CVE were defined as: 1) Ischemic heart disease (IHD): myo-
cardial infarction (MI, confirmed by electrocardiography and a
rise in plasma creatine kinase, muscle and brain fraction (CK-
MB) or troponin T) or angina pectoris (confirmed by exercise
stress test).
2) Ischemic cerebrovascular disease (ICVD): cerebral infarc-
tion (confirmed by computer tomography) or transitory
ischemic attacks (TIA, defined as transient focal symptoms
from the brain or retina with a maximum duration of 24 hours).
3) Ischemic peripheral vascular disease (IPVD): intermittent
claudication or peripheral arterial thrombosis/embolus (con-
firmed by angiogram or Doppler flow studies).
4) Death due to ischemic vascular disease: death due to myo-
cardial infarction, heart failure, sudden death, cerebral infarc-
tion, generalized atherosclerosis as stated by death certificate.
Laboratory Methods
High sensitivity C-reactive protein (CRP), α-1 antitrypsine,
fibrinogen and Serum Amyloid A (SAA) were measured using
BN ProSpec System (Dade Behring, Deerfield, IL, USA). C3
and C4 were analyzed using IMMAGE™ and C3d using an
ARRAY™ system (both instruments are from Beckman Coul-
ter, Brea, CA, USA). Albumin, apolipoprotein A1, apolipopro-
tein B and homocysteine were measured on an Architect
Ci8200 analyzer (Abbott Laboratories, Abbott Park, IL, USA).
Enzyme-linked immunosorbent assays (ELISA) were used to
measure Vascular cell adhesion molecule (VCAM-1, DY809,
R&D Systems, Minneapolis, MN, USA), vWF (antisera from
Dako (Glostrup, Denmark) calibrated against Liatest (Diagnos-Available online http://arthritis-research.com/content/11/6/R186
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Table 1
Baseline characteristics of patients
All patients
N = 182
Patients who developed CVE
N = 24




Age years 45 (31-53) 59 (49 to 66) 44 (30-52) < 0.0001
Male gender 10% 9% 11%
Smoking ever 51% 70% 46% 0.02
Hypertension 30% 42% 28%
Systolic blood pressure (mmHg)* 125 (115 to 140) 140 (120 to 143) 120 (110 to 140) 0.03
Hypercholestrolemia 41% 54% 39%
Total cholesterol (mmol/L) 4.9 (4.3 to 5.9) 5.7 (4.5 to 6.4) 4.9 (4.2 to 5.7) 0.05
LDL (mmol/L) 2.8 (2.3 to 3.5) 3.0 (2.7 to 4.0) 2.8 (2.2 to 3.5)
HDL (mmol/L) 1.4 (1.1 to 1.7) 1.3 (1.0 to 1.9) 1.4 (1.1 to 1.7)
Triglycerides (mmol/L)* 1.3 (1.0 to 1.9) 1.5 (1.2 to 2.0) 1.2 (0.9 to 1.9)
ApoB/ApoA*† 0.5 (0.3 to 0.6) 0.6 (0.4 to 0.8) 0.5 (0.3 to 0.6)
Diabetes 2% 0% 2%
Lupus manifestations
Disease duration 10 (4 to 18) 18 (10 to 24) 10 (4 to 17) 0.0005
Malar rash 58% 58% 58%
Discoid rash 22% 22% 22%
Photosensitivity 71% 50% 75% 0.01
Oral ulcers 29% 37% 27%
Arthritis 84% 100% 82% 0.02
Pleuritis 38% 65% 34% 0.005
Pericarditis 18% 17% 22%
Nephritis 30% 37% 29%
Neurological disorder 12% 17% 11%
Leucopenia 56% 57% 46%
Thrombocytopenia 21% 4% 24% 0.03
Previous venous occlusion 12% 29% 9% 0.004
SLICC >1 53% 79% 49% 0.006
SLAM >6 at baseline 45% 50% 44%
Medication
Months on steroid treatment* 35 (3 to 118) 54 (1 to 123) 31 (3 to119)
Cyclofosfamide treatment ever 15% 8% 16%
Azathioprine at baseline 38% 4% 33%
Chloroquine/Hydroxychloroquine at baseline 29% 21% 30%
Warfarin at baseline 9% 13% 8%
ASA at baseline 19% 25% 18%
Statins at baseline 0.6% 0% 0.7%
Autoantibodies againstArthritis Research & Therapy    Vol 11 No 6    Gustafsson et al.
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dsDNA 36% 33% 36%
CL IgG 47% 58% 46%
CL IgM 15% 21% 14%
β2GP-1 IgG† 36% 54% 34% 0.05
Lupus anticoagulant 21% 25% 20%
any PL 65% 83% 63% 0.05
SSA 43% 25% 46%
SSB 24% 13% 25%
Sm 11% 8% 12%
RNP 11% 14% 11%
Markers of systemic inflammation
hs CRP (mg/L)*† 1.9 (0.7 to 5.1) 4.9 (1.7 to 23.5) 1.7 (0.6 to 4.1) 0.0002
Fibrinogen (g/L)*† 3.4 (2.9 to 4.5) 4.6 (3.3 to 5.3) 3.2 (2.8 to 4.3) 0.002
α-1 antitrypsine (g/L)† 1.5 (1.3 to 1.7) 1.8 (1.4 to 2.2) 1.5 (1.3 to 1.7 0.002
SAA (mg/L)*† 5.0 (2.5 to 10.9) 9.3 (5.1 to 26.8) 4.5 (2.3 to 9.3 0.004
IL 6 (ng/L)*† 3.3 (2.0 to 6.9) 5.3 (2.7 to 10.9) 3.1 (1.9 to 6.4) 0.03







C4 (g/L)† 0.1 (0.1 to 0.2) 0.1 (0.09 to 1.4) 0.1 (0.1 to 0.2)
Markers of endothelial activation
sVCAM-1 (ng/L)*† 306 (252 to 385) 373 (303 to 503) 302 (249 to 375) 0.0009
von Willebrand factor %*† 117 (61 to 166) 157 (114 to 232) 112 (59 to 158) 0.001
Markers of renal damage
Creatinine (μmol/L)* 82 (73 to 94) 87 (76 to 107) 81 (72 to 93) 0.01
MDRD ml/min/1.73 m2 68 (57 to 80) 59 (45 to 71) 69 (58 to 81) 0.004
Blood urea nitrogen mmol/L† 5.7 (4.7 to 7.2) 6.5 (5.3 to 9.9) 5.6 (4.6 to 6.8) 0.01
Pathologic urine 23% 25% 22%
Other biomarkers
Albumin (g/L) 45 (41 to 48) 41(37 to 45) 45 (42 to 48) 0.002
Homocystein (μmol/L)*† 12.3 (10.0 to 15.6) 12.1 (10.4 to 17.9) 12.4 (9.8 to 15.4)
Distributions are given as % or median (interquartile range). P values, not adjusted for age, ≤ 0.05 are presented. * indicate not normally 
distributed variables. † indicate that analyses were done on frozen samples. Hypertension was defined as a systolic blood pressure >140 mm Hg 
and/or a diastolic blood pressure >90 mmHg and/or present treatment for hypertension. Hypercholesterolemia was defined as a total cholesterol 
level >5.2 mmol/L.
β2GP-1 = beta2glykoprotein-1; any PL = positive antibody test against CL IgG or IgM, β2GP-1 IgG or a positive lupus anticoagulant test; ApoB/
ApoA = apolipoprotein B/A. Disease manifestations were defined according to the 1982 revised American College of Rheumatology (ACR) 
criteria for classification of SLE [19]; C = Complement factor; C3d = Complement factor 3 degradation products; CL = cardiolipin; dsDNA = 
doublestranded DNA; HDL = high density lipoprotein; hsCRP = high sensitivity C reactive protein; IL-6 = interleukin 6; LDL = low density 
lipoprotein; MDRD = Estimated glomerular filtration rate using the Modification of Diet in Renal Disease (MDRD) formula [51]. Pathologic urine as 
defined by SLAM [20]; PL = phospholipid; RNP = r ibonucleoprotein; SAA = serum amyloid A; SLAM = a measure of disease activity [20]; 
SLICC = a measure of cumulative disease damage [21], Sm = Smith; SSA = Sjogrens syndrome A;
SSB = Sjogrens syndrome B; sVCAM-1 = soluble vascular cell adhesion molecule 1.
Pathologic urine as defined by SLAM [20].
Table 1 (Continued)
Baseline characteristics of patientsAvailable online http://arthritis-research.com/content/11/6/R186
Page 5 of 11
(page number not for citation purposes)
tica Stago, Asnieres, France), intra-assay coefficient of varia-
tion were <7%) and Interleukin 6 (IL-6, high sensitive ELISA,
HS600, R&D Systems, Minneapolis, MN, USA).
Antinuclear antibodies (ANA) were analysed by immunofluo-
rescence on sections of rat liver and HEp-2 cells (Immunocon-
cepts, Sacramento, CA, USA) and auto-antibodies to
Sjögren's syndrome A and B (SSA, SSB), Smith (Sm) and
Ribonucloprotein (RNP) using ANA-profile ELISA (Pharmacia
Diagnostics, Uppsala, Sweden), Innolia Immunoblot (Innoge-
netics, N.U. Ghent, Belgium), and Auto Immunodiffusion
(Immunoconcepts, Sacramento, CA, USA). Anti-double-
stranded DNA (dsDNA) antibodies were determined by IFL
using Crithidia lucillae kinetoplast assay (Immunoconcepts,
Sacramento, CA, USA). Anticardiolipin antibodies (aCL) were
measured by ELISA using ethanol fixed cardiolipin (Sigma-
Aldrich, St Louis, MO, USA) and HRP-conjugated rabbit
immunoglobulins against human IgG, respectively IgM (Dako,
Glostrup, Denmark). The levels of positivity were calibrated
against Harris standard (Louisville, LAPL-GM-001). Low aCL
level corresponded to 10-20, medium level to 20-80 and high
level to >80 GPL/MPL Units. The cut off values for positive
aCL was calculated to be at least the 95th percentile of healthy
blood donors. Autoantibodies to β2-glycoprotein1 (β2GP1,
IgG) were analysed by ELISA (Orgentec, Mainz, Germany).
Positive cut-off level was used according to the manufac-
turer's descriptions. Borderline results were regarded as neg-
ative. Lupus anticoagulant (LAC) was determined using a
modified Dilute Russel Viper Venom method, (Biopool, Umea,
Sweden) using Bioclot LAC.
Statistics
Patient characteristics were summarized for all patients and by
CVE occurrence and were compared using ANOVA, Mann-
Whitney U-test and X2 test as needed. Log transformation was
used for skewed continuous variables. Hazard ratios (HR) and
95% confidence intervals (95% CI) for the first CVE were cal-
culated in uni- and multivariable-adjusted Cox regression mod-
els for baseline factors.
Variables were first sorted into functional groups (traditional
risk factors, lupus manifestations etc. see Table 1 and 2). After
adjusting for age, the variables within each group, which were
representative and most significantly associated with future
CVEs were entered into a multivariable-adjusted model.
Because of a limited number of first CVEs, we restricted the
number of variables in the multivariable-adjusted model to four.
Calculations were done using JMP software (SAS Institute,
Carey, North Carolina, USA). A P value < 0.05 was consid-
ered statistically significant.
Results
Baseline data and clinical manifestations
As expected, patients who developed a first CVE were older,
more likely to have ever smoked, have higher total cholesterol
levels and to have higher systolic blood pressure. Furthermore,
they had a longer mean SLE duration, were more likely to have
had previous venous occlusion, pleuritis, arthritis and leucope-
nia but were less likely to have photosensitivity or thrombocy-
topenia. Several markers of systemic inflammation, endothelial
activation and renal damage, together with aPL, were elevated
at baseline in patients who developed a first CVE (Table 1).
Cardiovascular events
Surviving patients were reinvestigated after a mean time of 8.3
± 1.2 years. A total 132 patients were examined in person, and
34 through a structured telephone interview. Fifteen patients
were deceased and their death certificates were investigated.
Five autopsies had been performed and all protocols were
reviewed. Medical files were reviewed for all with the exception
of one patient who was unwilling to participate at follow up,
thus her history of CVE could not be determined.
Twenty-four new CVEs occurred, three of which were fatal
(two heart failures, one atherosclerosis according to death
certificates) (Table 3).
Prospective evaluation of risk factors for CVEs
As expected, age was a strong predictor of the first CVE, we
therefore adjusted all measurements for age. Thereafter, only
smoking of the traditional risk factors remained as a predictor
of CVEs. Of lupus manifestations arthritis, pleuritis, previous
venous occlusion and absence of thrombocytopenia were
associated with first CVEs. Among biomarkers aPL (aCL IgG,
β GP1 IgG and any aPL), fibrinogen, markers of endothelial
activation (sVCAM-1 and vWf), low levels of plasma albumin,
and absence of SSB antibodies remained as predictors of the
first CVE. All patients with a first CVE had arthritis, and none
had diabetes, therefore these variables could not be further
evaluated (Table 2). In a multivariable-adjusted model age, any
positive aPL, and vWf were positively associated with CVEs,
while thrombocytopenia was inversely associated (Table 4). In
an alternative model we exchanged vWf for sVCAM-1. sVCAM
remained in this model, together with the other variables in
Table 4, as an independent predictor of CVEs (Relative Risk
for sVCAM-1 = 2.11, 95%CI (1.24 to 3.58), P = 0.005).
Discussion
This is, to our knowledge, the first study to investigate predic-
tors of the first ever CVE in SLE and a novel observation is that
high levels of endothelial markers precede these events. We
also identified SLE manifestations and can confirm [8] occur-
rence of aPLs as predictors of first CVEs. It is of note that, with
the exception of age and smoking, traditional CAD risk factors
did not explain CVEs in this study.
In healthy individuals high circulating levels of vWf predicted
CVEs in several studies [23,24], but in contrast to this study,
significance did not remain after adjustment for other CAD risk
factors [24,25]. Myocardial infarctions are common in condi-Arthritis Research & Therapy    Vol 11 No 6    Gustafsson et al.
Page 6 of 11
(page number not for citation purposes)
Table 2
Baseline predictors of the first ever cardiovascular event, page-adjusted Cox regression models
Hazard Ratio 95% Confidence interval P
Traditional risk factors
Age univariate 2.28* 1.67 to 2.10 < 0.0001
Age adjusted
Male gender 0.71 0.11 to 2.41
Smoking, ever 2.62 1.11 to 7.03 0.03
Hypertension 0.72 0.30 to 1.70
Systolic blood pressure 0.78 0.52 to 1.18
Hypercholesterolemia 1.37 0.61 to 3.14
Total cholesterol 1.19 0.81 to 1.74
LDL 1.23 0.80 to 1.89
HDL 0.77 0.34 to 1.62
Triglycerides† 1.21 0.86 to 1.69
ApoB/ApoA† 1.36 0.88 to 2.10
Diabetes ‡ ‡ 0.02
Manifestations of Lupus
Disease duration 1.28 0.98 to 1.68
Malar rash 1.09 0.72 to 1.67
Discoid lupus 0.80 0.45 to 1.26
Photosensitivity 0.69 0.46 to 1.04
Oral ulcers 1.40 0.90 to 2.14
Arthritis § § 0.002
Pleuritis 1.60 1.02 to 2.46 0.04
Pericarditis 1.35 0.77 to 2.16
Nephritis 1.31 0.85 to 1.97
Leukopenia 0.94 0.62 to 1.42
Thrombocytpenia 0.37 0.09 to 0.83 0.009
Neurologic disorder 0.78 0.48 to 1.44
Previous venous occlusion 1.88 1.16 to 2.90 0.01
SLICC>1 1.91 0.74 to 5.97
SLAM>6 at baseline 1.25 0.83 to 1.87
Medications
Months on steroid treatment 1.00 0.68 to 1.48
Cyclofosfamide treatment ever 0.60 0.01 to 2.03
Azathioprine at baseline 0.51 0.03 to 2.47
Chloroquine/Hydroxychloroquine at baseline 1.01 0.32 to 2.67
Warfarin at baseline 1.45 0.34 to 4.27
ASA at baseline 1.54 0.55 to 3.70
Autoantibodies against
dsDNA 1.41 0.57 to 3.25Available online http://arthritis-research.com/content/11/6/R186
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CL IgG 2.57 1.13 to 6.13 0.02
CL IgM 1.35 0.45 to 3.41
β2GP1 IgG 2.57 1.13 to 5.99 0.02
Lupus anticoagulant 1.10 0.40 to 2.63
Any aPL 4.90 1.76 to 17.72 0.002
SSA 0.66 0.39 to 1.03
SSB 0.57 0.27 to 1.00 0.05
Sm 1.21 0.48 to 2.29
RNP 1.60 0.76 to 2.87
Markers of systemic inflammation
hs CRP† 1.36 0.85 to 2.18
Fibrinogen† 1.72 1.10 to 2.68 0.02
α-1 antitrypsine 1.49 1.01 to 2.18
SAA† 1.36 0.88 to 2.09
IL 6† 1.26 0.87 to 1.82
C3 0.92 0.63 to 1.35
C3d 1.38 0.85 to 2.22
C4 0.82 0.56 to 1.18
Markers of endothelial activation
sVCAM-1† 1.78 1.20 to 2.65 0.005
von Willebrand factor† 2.05 1.23 to 3.42 0.004
Markers of renal involvement
Creatinine† 1.17 0.74 to 1.85
MDRD 1.07 0.57 to 2.00
Blood urea nitrogen 1.15 0.75 to 1.77
Pathological urine 2.4 0.8 to 6.1
Other biomarkers
Albumin(g/l) 0.56 0.41 to 0.78 0.002
Homocystein (μmol/l)† 0.79 0.52 to 1.21
Calculations were done using age-adjusted Cox regression. For continuous variables Hazard Ratio (HR) is given as risk per standard deviation, 
*For age HR is calculated per 10 years (HR/10 years). †calculations were done on log transformed values. P values ≤ 0.05 are presented. ‡ 
Infinite coefficient, due to no AE in the diabetes group. §Infinite coefficient, due to all AE in the arthritis group, confidence interval could thus not 
be determined for these two variables. Hypertension was defined as a systolic blood pressure >140 mm Hg, and/or a diastolic blood pressure 
>90 mmHg and/or present treatment for hypertension. Hypercholesterolemia was defined as a total cholesterol level >5.2 mmol/L.
β2GP-1 = beta2glykoprotein-1; β2GP-1 IgG or a positive lupus anticoagulant test;
any PL = positive antibody test against CL IgG or IgM; ApoB/ApoA = apolipoproteinB/A. Disease manifestations were defined according to the 
1982 revised American College of Rheumatology (ACR) criteria for classification of SLE [19]; C = Complement factor; C3d = Complement factor 
3 degradation products; CL = cardiolipin; dsDNA = doublestranded DNA; HDL = high density lipoprotein; hsCRP = high sensitivity C reactive 
protein; IL-6 = interleukin 6; LDL = low density lipoprotein;
MDRD = Estimated glomerular filtration rate using the Modification of Diet in Renal Disease (MDRD) formula [51]. Pathologic urine as defined by 
SLAM [20]; PL = phospholipid; RNP = ribonucleoprotein; SAA = serum amyloid A; SLAM = a measure of disease activity [20]; SLICC = a 
measure of cumulative disease damage [21]; Sm = Smith; SSA = Sjogrens syndrome A; SSB = Sjogrens syndrome B; sVCAM-1 = soluble 
vascular cell adhesion molecule 1.
Table 2 (Continued)
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tions with high levels of vWf. Plasma levels rise during acute
coronary syndromes and high levels predict less favorable
long time outcome in patients with established CVD, as
recently reviewed by Spiel et.al [26]. Inflammatory cytokines
can cause release of vWf from endothelial cells into the circu-
lation where vWf has pro-thrombotic effects as it promotes
aggregation of platelets [26]. SLE patients with subclinical
atherosclerosis have increased vWf activity in the circulation
[27] and vWf was furthermore induced by IgG from patients
with SLE and thrombotic diseases [28] and by anti DNA anti-
bodies in experimental studies [29]. The high activity of vWf in
lupus [27,30] may thus be attributable to both pro-inflamma-
tory cytokines and to autoantibodies, and could directly con-
tribute to the high incidence of CVE in SLE.
VCAM-1, an endothelial adhesion molecule is shed into the
circulation when the endothelium is activated. In SLE, levels of
sVCAM-1 are elevated and correlate with disease activity [31],
renal manifestations [32] and aPL [33]. We have recently
demonstrated that after adjustment for nephritis, high levels of
sVCAM-1 discriminated SLE patients with manifest CVD from
SLE patients free of CVD and population controls [34]. The
present study extends these findings as we can report that
high levels of sVCAM-1 predict future CVE, independently of
aPLs. VCAM-1 has also been reported to predict poor long-
term outcome in other patient groups at risk of CVD, that is, in
hemodialysis patients [35], in patients with diabetic nephrop-
athy [36] and in patients with manifest CAD [37]. Both vWf
and VCAM-1 are markers of endothelial activation. Other stud-
ies have reported impaired endothelial function as measured
by flow mediated dilatation [38] and that increased numbers
of circulating apoptotic endothelial cells are present in SLE
patients [39]. Taken together many studies report that
endothelial perturbation occurs in SLE, and our results sug-
gest that it precedes the first CVE.
In the general population, systemic inflammatory activity, often
measured by CRP, is a well-documented risk factor for CVD.
A similar role for fibrinogen, SAA and IL-6, has also been
reported [40]. At baseline elevation of several inflammatory
markers were more prevalent among patients who experi-
enced their first CVE during follow-up, but after adjustment for
age, only fibrinogen remained as a significant predictor. Fibrin-
ogen is an important clotting protein, and high levels have
been reported in SLE patients with a history of thrombotic dis-
ease [41]. CRP has previously been identified as a risk factor
for arterial disease in SLE, but we were not able to replicate
those results [8].
Patients with a positive test for any aPL had a higher risk of
CVEs confirming previous findings by Toloza et.al [8]. Positive
IgG titers of aCL, or β2GP1, were predictive of CVE. However,
IgM aCL and LAC were not. Any positive aPL were more com-
mon in this study (65%) than reported in most [7,33,42] lupus
Table 3
Age at and type of first cardiovascular event
Type of cardiovascular event Number of events Median age at onset Age range
All cardiovascular events 24 64.4 40.6 to 85.1
Ischemic heart disease 10 60.8 40.6 to 85.1
Ischemic cerebrovascular disease 6 65.7 49.9 to 83.9
Ischemic peripheral vascular disease 5 55.1 44.1 to 82.4
Death due to cardiovascular disease 3 64.7 58.1 to 68.6
Ischemic heart disease = myocardial infarction or angina pectoris, ischemic cerebrovascular disease = cerebral infarction or transitory ischemic 
attacks, ischemic peripheral vascular disease = intermittent claudication or peripheral arterial thrombosis/embolus, death due to ischemic vascular 
disease = death due to myocardial infarction, heart failure, sudden death, cerebral infarction, generalized atherosclerosis as stated by death 
certificate.
Table 4
Baseline predictors of the first ever cardiovascular event, multivariable-adjusted Cox regression
Hazard Ratio Confidence interval P
Age* 2.39 1.71 to 3.32 < 0.0001
Thrombocytopenia 0.35 0.08 to 0.77 0.005
Any aPL 4.23 1.56 to 14.83 0.003
von Willebrand factor† 1.97 1.16 to 3.33 0.01
Calculations were done using multivariable-adjusted Cox regression. *For age hazard ratio is calculated per 10 years (HR/10 years), for von 
Willebrand factor hazard ratio is given as risk per standard deviation, †calculations were done on log transformed values.Available online http://arthritis-research.com/content/11/6/R186
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cohorts possibly indicating a low cut-off level at our laboratory
in the mid 90's when baseline data were collected. It is there-
fore interesting to note that any aPL were only predictive of
CVEs when we included the cut-off for positive tests. With a
cut-off at medium titer, more in accordance with the definition
of the anti-phospholipid syndrome (APS) [43], baseline aPLs
were no longer significantly associated with future CVE (data
not shown). This may be explained by limited power, as few
patients had medium/high titer aPL, and by the fact that these
patients were more often on anti-coagulation treatment. Nev-
ertheless, our results suggest that also low titer aPL adds to
the risk of CVEs in SLE patients.
We noted that subsets of patients with different lupus mani-
festations seemed to have a differentiated risk of CVE. Arthritis
and pleuritis are SLE manifestations, often associated with a
more pronounced acute phase response [15,44], and patients
with these symptoms had a higher risk of developing a first
CVE, as also reported by Mok et al [16]. Patients with a previ-
ous episode of venous occlusion, a major manifestation of
APS [43], were more likely to present with a first CVE. They
were also more likely to have any positive aPL (Odds Ratio =
12.5, 95% CI (1.6 to 95.7), P = 0.0005). The observation that
patients with previous thrombocytopenia, also associated with
APS [43], were at lower risk of CVEs is new. Previous studies
have demonstrated that thrombocytopenia is often associated
with auto antibodies to platelet glycoproteins, but these anti-
bodies have not been linked to thrombosis [45]. Hypothetically
a low platelet count could confer a protective anti-coagulant
effect, but this would need to be tested in larger samples.
Another novel observation is that patients with photosensitivity
and SSA/SSB antibodies, which often occur together, may be
at lower CVD risk as compared to other SLE patients. Taken
together, this study suggests that subgroups of SLE patients
are not affected with the same high risk of CVEs. Larger cohort
studies are needed to confirm these observations.
Besides age, smoking was the only traditional CVD risk factor
which predicted CVEs in this study, this is in line with the
results of Toloza et al [8] Lipid derangements including hyper-
cholesterolemia, elevated ApoB/ApoA ratio, low HDL and
hypertriglyceridemia, did not remain statistically significant
after adjustment for age. Earlier studies are inconsistent with
regard to the impact of blood lipids on CVD in SLE. Some
have reported an association between manifest CVD and
hypercholesterolemia [46,47], hypertriglyceridemia [48,49] or
low HDL [4,16] whereas this study and the prospective study
from the LUMINA cohort did not find an association [8].
After adjusting for age, a lower estimated glomerular filtration
rate at baseline was not predictive of presenting with a first
CVE in this study. Hypoalbuminemia, positively associated
both with markers of systemic inflammation and with loss of
renal function (data not shown), was however a strong predic-
tor. It was not entered into the multivariable-adjusted model
because we regarded it as a proxy for both systemic inflamma-
tion and for renal disease. Its significance may however be
useful since albumin measurements are inexpensive and com-
monly used in clinical practice.
The relatively small number of patients and events in the
present study are limitations, which call for some caution, in
particular with regard to subgroup analysis. It may also explain
the lack of association with traditional CAD risk factors. The
great majority of our patients were Caucasians of European
origin, thus confirmation in other ethnic groups is needed
before generalizing our results to SLE cohorts from other parts
of the world. The detailed baseline information and the rela-
tively long and almost complete follow-up including all
deceased patients are strengths of the study. The fact that we
only included the first ever CVE is a merit, but also a reason for
the low number of events. Several patients eventually experi-
enced additional events. Of note 9/24 patients (38%) who
experienced a first CVE were dead when we closed the study
in 2007. This figure further highlights the importance of con-
ducting longitudinal prospective studies.
Due to the design of this study and the clinical definitions used
for CVEs it was not possible to compare the incidence of
CVEs in these lupus patients with the general population.
However, other studies have shown that patients with SLE
have a marked increased risk of CVD as compared to the gen-
eral population [2,15,50].
Conclusions
In conclusion this prospective study is the first to investigate
lupus associated and CAD risk factors for the first ever CVE in
patients with SLE. In addition to age, positive aPL, biomarkers
indicating increased endothelial cell activity/damage, and
absence of thrombocytopenia were independent predictors of
CVEs. Our results indicate that activation of the endothelium
and the coagulation system are important features in SLE
related CVD. Furthermore, the risk of CVEs seems to differ
between subgroups of SLE patients. How these findings influ-
ence and interact with the presence of premature atheroscle-
rosis, not measured in this study, remains to be determined.
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